Could Daily Monitoring of Fibrin Related Markers Help Suspect a Thrombotic Event in COVID-19 Patients? A Prospective Pilot Study
暂无分享,去创建一个
T. Lecompte | F. Mullier | A. Dive | M. Hardy | I. Michaux
[1] S. Laporte,et al. Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study , 2020, Hämostaseologie.
[2] Y. Komiyama,et al. Characterization of fibrin/fibrinogen degradation products reagents and their utility in critical care patients with enhanced fibrinolysis , 2020, International journal of laboratory hematology.
[3] Melanie S Wooten,et al. Retrospective Analyses Associate Hemostasis Activation Biomarkers With Poor Outcomes in Patients With COVID-19 , 2020, American journal of clinical pathology.
[4] S. Laporte,et al. Prothrombotic hemostasis disturbances in patients with severe COVID-19: Individual daily data , 2020, Data in Brief.
[5] Emma M Schatoff,et al. D-dimer cut-off points and risk of venous thromboembolism in adult hospitalized patients with COVID-19 , 2020, Thrombosis Research.
[6] J. Thachil,et al. Biomarkers for the prediction of venous thromboembolism in critically ill COVID-19 patients , 2020, Thrombosis Research.
[7] T. Soumagne,et al. Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients , 2020, European Respiratory Journal.
[8] L. Alberio,et al. Utility of D-dimers and intermediate-dose prophylaxis for venous thromboembolism in critically ill patients with COVID-19 , 2020, Thrombosis Research.
[9] J. Mascarenhas,et al. Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19 , 2020, Thrombosis Research.
[10] D. Gommers,et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19 , 2020, Thrombosis Research.
[11] G. Lippi,et al. D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis , 2020, Thrombosis and Haemostasis.
[12] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[13] M. Refaai,et al. The Clinical Significance of Fibrin Monomers , 2018, Thrombosis and Haemostasis.
[14] J. Thachil,et al. A re‐evaluation of the D‐dimer cut‐off value for making a diagnosis according to the ISTH overt‐DIC diagnostic criteria: communication from the SSC of the ISTH , 2018, Journal of thrombosis and haemostasis : JTH.
[15] B. Sangro,et al. Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[16] C. Downey,et al. The clinical utility of fibrin-related biomarkers in sepsis , 2013, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[17] Martin Borggrefe,et al. Use of soluble fibrin antigen instead of D-dimer as fibrin-related marker may enhance the prognostic power of the ISTH overt DIC score , 2004, Thrombosis and Haemostasis.
[18] M. Hennerici,et al. Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant tissue plasminogen activator. , 1999, Stroke.
[19] C. Dempfle,et al. The Use of Soluble Fibrin in Evaluating the Acute and Chronic Hypercoagulable State , 1999, Thrombosis and Haemostasis.